Kalydeco slows CF disease progression over time, study finds
Treatment with Kalydeco (ivacaftor) for almost eight years consistently improved lung function and reduced mortality in people with cystic fibrosis (CF), according to a study looking at several measures of disease progression. The therapy also significantly improved nutritional status, which together with reduced pulmonary exacerbations, hospitalizations, and lung…